Literature DB >> 11578469

Extended radical hysterectomy in early-stage carcinoma of the uterine cervix: tailoring the radicality.

E. Sartori1, L. Fallo, B. La Face, U.A. Bianchi, S. Pecorelli.   

Abstract

The question of whether surgical treatment in early-stage cervical cancer should be aggressive or restricted to less radical techniques is still controversial. To answer this question it was thought useful to investigate the correlation of parametrial lymph node metastases with extension and stage of disease. Two-hundred and sixty-three consecutive primary radical surgical procedures were performed in our institute in clinical stage IB or stage IIA cervical cancer. Positive parametrial nodes were found in 6.9% of cases: 5% in stage IB (3% in the proximal part of the parametrium and 2% in the distal part, near the pelvic wall) and 16.3% in stage IIA (7% proximal and 9.3% distal) (P = 0.0193). During a median follow-up period of 92 months, disease recurred in 17.1% and 17.6% of cases, in negative and positive parametria, respectively. The 5-year overall and disease-free survival rates were 80.4% and 81.6% for patients with negative and positive parametria, respectively. From this experience it is concluded that the extent of radical hysterectomy should be related to the extent of the disease on the basis of modern knowledge of the pattern of spread. The principal key to prognosis remains pelvic and paracavoaortic nodal status.

Entities:  

Year:  1995        PMID: 11578469     DOI: 10.1046/j.1525-1438.1995.05020143.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  Class I hysterectomy in stage Ia2-Ib1 cervical cancer.

Authors:  Long Chen; Wei-Na Zhang; Sheng-Miao Zhang; Yuan Gao; Tian-Hong Zhang; Ping Zhang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-06-29       Impact factor: 1.195

2.  Simple Hysterectomy for Patients with Stage IA2 Cervical Cancer: A Retrospective Cohort Study.

Authors:  Qing Liu; Yu Xu; Yuedong He; Yi Du; Qianwen Zhang; Ya Jia; Ai Zheng
Journal:  Cancer Manag Res       Date:  2021-10-13       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.